



**PRÓ-REITORIA DE PESQUISA E PÓS-GRADUAÇÃO
MESTRADO EM CIÊNCIA ANIMAL**

**EXPRESSÃO DIFERENCIAL DO RECEPTOR DE LH, DA PROTEÍNA DE
LIGAÇÃO DE MRNA DO LHR, BTA-MIR-222 E ENZIMAS ESTEROIDOGÊNICAS
NO OVÁRIO BOVINO EM DESENVOLVIMENTO**

MARINA PLATZECK CHAVES

**EXPRESSÃO DIFERENCIAL DO RECEPTOR DE LH, DA PROTEÍNA DE
LIGAÇÃO DE MRNA DO LHR, BTA-MIR-222 E ENZIMAS ESTEROIDOGÊNICAS
NO OVÁRIO BOVINO EM DESENVOLVIMENTO**

MARINA PLATZECK CHAVES

Defesa apresentada a Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Oeste Paulista, como parte dos requisitos para obtenção do título de Mestre em Ciência Animal - Área de Concentração: Fisiopatologia Animal.

Orientador: Prof. Dr. Anthony César de Souza Castilho

MARINA PLATZECK CHAVES

**EXPRESSÃO DIFERENCIAL DO RECEPTOR DE LH, DA PROTEÍNA DE
LIGAÇÃO DE MRNA DO LHR, BTA-MIR-222 E ENZIMAS
ESTEROIDOGÊNICAS NO OVÁRIO BOVINO EM DESENVOLVIMENTO**

Defesa apresentada a Pró-Reitoria de Pesquisa e Pós-Graduação, Universidade do Oeste Paulista, como parte dos requisitos para obtenção do título de Mestre em Ciência Animal - Área de Concentração: Fisiopatologia Animal.

Presidente Prudente, 30 de maio 2018.

BANCA EXAMINADORA

Prof. Dr. Anthony César de Souza Castilho
Universidade do Oeste Paulista – Unoeste
Presidente Prudente-SP

Prof. Dr. Luiz Gustavo de Almeida Chuffa
Departamento de Anatomia – Instituto de Biociências
Universidade Estadual Paulista – Unesp
Botucatu-SP

Profa. Dra. Ines Cristina Giometti
Universidade do Oeste Paulista – Unoeste
Presidente Prudente-SP

AGRADECIMENTOS

Agradeço, sobretudo, ao Prof. Dr. Anthony César de Souza Castilho, meu orientador, que sempre com muita paciência pôde dispor de seu tempo para me passar um pouco de seu conhecimento. Serei sempre muito grata.

A todos os colegas de nossa equipe: Patrícia Fontes, Priscila Santos, Leonardo Mendes, Alan Giroto. Tenho um carinho muito grande por vocês, e agradeço pelo que cada um me ensinou no decorrer de todos esses meses.

Eu gostaria de agradecer também as alunas Vitória Guilherme e Thaisy Dellaqua, do laboratório da UNESP Campus Assis, que são muito queridas, e me ajudaram muito no laboratório e também a campo nas coletas, muito obrigada.

Agradecimentos ao programa de Mestrado em Ciência Animal e a Pró-Reitoria de Pesquisa e Pós Graduação da Universidade do Oeste Paulista.

A CAPES e FAPESP pela concessão da bolsa de estudos/auxílio financeiro.

“Antes da descoberta da Austrália, as pessoas do Mundo Antigo estavam convencidas de que todos os cisnes eram brancos. Uma crença inquestionável por evidências empíricas. Deparar-se com o primeiro cisne negro pode ter sido uma surpresa interessante para alguns ornitólogos. Mas não é essa a importância da história. Ela ilustra a limitação do aprendizado por meio de observações ou experiências e a fragilidade do nosso conhecimento. Uma única observação pode invalidar uma afirmação originada pela existência de milhões de cisnes brancos. Tudo o que se precisa é de um único pássaro negro (que também, pelo que sei, é muito feio).” – A Lógica do Cisne Negro (Nassim Nicholas Taleb)

RESUMO

EXPRESSÃO DIFERENCIAL DO RECEPTOR DE LH, DA PROTEÍNA DE LIGAÇÃO DE MRNA DO LHR, BTA-MIR-222 E ENZIMAS ESTEROIDOGÊNICAS NO OVÁRIO BOVINO EM DESENVOLVIMENTO

Esteroides e gonadotrofinas são essenciais para a regulação do desenvolvimento folicular antral e os estágios finais do desenvolvimento pré-antral. Embora o receptor do hormônio luteinizante (LHR) tenha sido detectado nos folículos pré-antrais de ratos, coelhos e porcos, a expressão deste receptor no ovário fetal bovino não foi demonstrada. O presente estudo teve como objetivo quantificar a expressão do LHR e a abundância de mRNA da proteína de ligação LHR (LRBP), STAR, HSD3B1, CYP17A1 e CYP19A1 durante o desenvolvimento do ovário fetal bovino. Além disso, objetivamos identificar e quantificar a expressão de bta-miR-222 (microRNA regulador do gene LHCGR). Em resumo, a expressão de LHR foi observada no folículo pré-antral no ovário fetal de bovino e a abundância de mRNA foi menor no dia 150 do que no dia 60. No entanto, a abundância de mRNA da LRBP seguiu o padrão oposto. Semelhante a LRBP, a abundância de bta-miR-222 foi maior no dia 150 do que no dia 60 ou 90. Com relação à expressão gênica de enzimas esteroideogênicas; apenas a abundância de mRNA de STAR foi maior no dia 150 do que no dia 60. A proteína LHR foi detectada em oogônia, folículos primordiais, primários e secundários. Além disso, ambos os oócitos e células da granulosa apresentaram imunolocalização positiva para LHR. Em conclusão, estes resultados sugeriram o envolvimento da regulação do LHCGR / LRBP com mecanismos relacionados ao desenvolvimento de folículos pré-antrais, especialmente durante o estabelecimento de folículos secundários. Além disso, os presentes dados reforçaram que a expressão reduzida de mRNA de LHR em ovários fetais bovinos no dia 150 estava relacionada à maior expressão de LRBP e bta-miR-222.

Palavras-chave: LHCGR, mevalonato quinase, folículo pré-antral, esteroideogênese, microRNAs

LISTA DE FIGURAS

- FIGURA 1 - Relative mRNA abundance of LHCGR (A), LRBP (B), and bta- 18
miR222 (C) between 60 and 150 days of gestation. The data are
presented as the mean (\pm S.E.M.). Bars with different letters are
significantly different ($P \leq 0.05$).
- FIGURA 2 - Representative photomicrographs showing immunolocalization 19
of LHR protein in bovine fetal ovary. Overview LHR staining in
cortex (C) and medulla (M) with immunostaining in the ovarian
surface (curve arrow) (A). The ovarian cortex showed granulosa
LHR positive cells in secondary (thick arrow), primary (thin
arrow) and primordial (dashed arrow) follicles as well as stromal
positive cells (circle) (B). Corpus luteus (CL) was used as
positive control and the adult ovary stroma (ST) are not stained
(C). Strong immunoreactivity in cytoplasm of small luteal cells
(asterisk) and weak immunoreactivity in large luteal cells
(hashtag) are evident (D). Bars: A and B: 100 μm ; C – D: 50
 μm .
- FIGURA 3 - Relative mRNA abundance of STAR, HSD3B1, CYP17A1, and 20
CYP19A1 between 60 and 150 days of gestation. The data were
presented as the mean (\pm S.E.M.). Bars with different letters (a
and b) are significantly different ($P \leq 0.05$).

LISTA DE TABELAS

Tabela 1 -	Primers used in RT-q PCR	15
Tabela 2 -	Details of miRNA assays used in RT-qPCR.	16

SUMÁRIO

1	ARTIGO	10
2	ANEXO	29

O presente manuscrito está formatado conforme as normas do periódico *Animal
Reproduction Science*.

203 **Differential expression of LH receptor, LHR mRNA binding protein, bta-miR-222 and**
204 **steroidogenic enzymes in the developing bovine ovary**

205

206 M.P. Chaves¹; A.B. Giroto¹; P. H. dos Santos²; P. K. Fontes²; L. O. Mendes¹; A. C. S.
207 Castilho^{1*}

208

209 ¹Universidade do Oeste Paulista, Presidente Prudente – SP, Brasil.

210 ²Universidade Estadual Paulista “Júlio de Mesquita Filho”, Departamento de Farmacologia,
211 Instituto de Biociências, Botucatu, SP, Brasil.

212

213

214

215 * Corresponding author: Universidade do Oeste Paulista, Pró-reitora de Pesquisa e Pós-
216 graduação - Campus II Rodovia Raposo Tavares, km 572 - Bairro Limoeiro CEP 19067-175 -
217 Presidente Prudente – SP, Brasil. E-mail: castilho.anthony@gmail.com

218

219

220

221

222

223

224

225 **ABSTRACT**

226 Steroids and gonadotrophins are essential for the regulation of antral follicular development
227 and the late stages of preantral development. Although the luteinizing hormone receptor
228 (LHR) has been detected in the preantral follicles of rats, rabbits, and pigs, the expression of
229 this receptor in bovine fetal ovary has not been demonstrated. The present study aimed to
230 quantify the expression of the LHR and the mRNA abundance of the genes LHR binding
231 protein (LRBP), STAR, HSD3B1, CYP17A1, and CYP19A1 during the development of
232 bovine fetal ovary. In addition, we aimed to identify and quantify the expression of bta-miR-
233 222 (a regulatory microRNA of the LHCGR gene). In summary, LHR expression was
234 observed in the preantral follicle in bovine fetal ovary, from oogonias to primordial, primary
235 and secondary stages, and the mRNA abundance was lower on day 150 than day 60.
236 However, the mRNA abundance of LRBP followed the opposite pattern. The LHR protein
237 was detected in oogonia, primordial, primary, and secondary follicles. Moreover, both oocytes
238 and granulosa cells showed positive immunostaining for LHR. Similar to LRBP, the
239 abundance of bta-miR-222 was higher on day 150 than day 60 or 90 of gestation. With regard
240 to the gene expression of steroidogenic enzymes; only the mRNA abundance of STAR was
241 higher on day 150 than on day 60. In conclusion, these results suggested the involvement of
242 LHCGR/LRBP regulation with mechanisms related to the development of preantral follicles,
243 especially during the establishment of secondary follicles. Furthermore, the present data
244 reinforced that the reduced expression of LHR mRNA in bovine fetal ovaries on day 150 was
245 related to the higher expression of LRBP and bta-miR-222.

246 *Key words:* LHCGR, mevalonate kinase, preantral follicle, steroidogenesis, microRNAs.

247 **1. Introduction**

248 In cattle, all preantral follicular stages occur in the fetal ovary during pregnancy
249 (Erickson, 1966). After formation, the quiescent primordial follicles begin their growth;
250 subsequently, the granulosa cells multiply and change to a cuboidal shape, setting the
251 transition from the primordial to the primary follicle (Wandji et al., 1996). In the bovine fetus,
252 (Castilho et al., 2014) demonstrated that the preantral follicular dynamics in zebu were similar
253 to those described in taurines (Tanaka et al., 2001): primordial follicles appeared at 75 days of
254 gestation, primary at 90 days, secondary at 150 days, and early antral follicles at 210 days of
255 gestation.

256 Although fetal ovarian development occurs independently of gonadotrophins, these
257 hormones do influence this process (Fortune and Eppig, 1979). As follicle stimulating
258 hormone (FSH) receptors (FSHR) have been detected in bovine primary follicles (Wandji et
259 al., 1996), the primary role of FSH at this stage of development cannot be excluded (Gutiérrez
260 et al., 1997; McNatty et al., 1999; Gutierrez et al., 2000; Webb et al., 2003). Unlike FSHR,
261 there are no studies that report the expression and regulation of LHR in different preantral
262 follicular types during fetal ovarian development in bovine species.

263 Luteinizing hormone (LH) plays a key role in the control of physiological processes in
264 the ovary, such as the development of antral follicles and ovulation (Xu et al., 1995). In antral
265 follicles, the LH receptors have been detected in theca cells of healthy follicles and,
266 subsequently, in granulosa cells (Xu et al., 1995; Bao et al., 1997; Fortune, 2001; Fortune et
267 al., 2001; Garverick et al., 2002; Nogueira et al., 2007; Ereno et al., 2015). The possible
268 mechanisms involved in the LHR regulation of granulosa cells include the LH receptor
269 binding protein (LRBP) and certain microRNAs. LRBP is a mRNA binding protein that binds
270 to the LHCGR (LHR gene) coding region and represses its translation (Nair et al., 2002). In
271 cattle, Ereno et al. (2015) first demonstrated the inverse correlation between LRBP expression

272 and LHCGR mRNA regulation at the time of follicular deviation in granulosa cells. Similarly,
273 recent studies demonstrated that the post-transcriptional regulation of LHCGR by miRNA
274 occurs in the ovary of several species (Menon et al., 2013; Troppmann et al., 2014; Menon et
275 al., 2015; Gilchrist et al., 2016); this includes miR-222, which was suggested by Hossain et al.
276 (2009) as a possible regulator of LHCGR expression. Salilew-Wondim et al. (2014)
277 investigated the expression of miR-222 in the theca and granulosa cells of bovine antral
278 follicles and reported lower expression in the granulosa cells from dominant follicles. In
279 addition, Santos et al. (2018) reported lower miR-222 expression in granulosa cells from
280 superstimulated cows submitted to ovarian superstimulation than control animals and inverse
281 proportionality to the abundance of LHCGR mRNA.

282 The steroid hormones and their actions are directly dependent on the expression of
283 gonadotrophic receptors and steroidogenic enzymes in follicular somatic cells (Fortune et al.,
284 2001). Although there is evidence that the developing gonads produce steroids throughout
285 gestation (Shemesh et al., 1978; Tanaka et al., 2001), probably by using the same sequential
286 enzymatic processing of the adult ovary (Conley and Bird, 1997), the role of steroids during
287 the development of bovine ovaries has not been sufficiently clarified.

288 Thus, the objectives of the present study were to localize and quantify the LHR
289 expression in the fetal ovary and to measure the mRNA abundance of LRBP and expression
290 of bta-miR-222 in the developing bovine fetal ovary. In addition, we sought to quantify the
291 mRNA abundance of genes encoding steroidogenic enzymes STAR (StAR protein), HSD3B1
292 (3 Beta-Hydroxysteroid Dehydrogenase), CYP17A1 (17 Steroid - Alpha Monooxygenase) and
293 CYP19A1 (Aromatase).

294

295

296 **2. Materials and methods**

297 *2.1. Tissues*

298 In accordance with the methods of Tanaka et al. (2001) and Castilho et al. (2014), 20 female
299 fetuses at 60, 90, 120, and 150 days of gestational (n = 5/group), predominantly from Nellore
300 cattle (*Bos Taurus indicus*), were obtained from a local abattoir near the University of São
301 Paulo State campus at Assis city and were classified according to specific crown-rump lengths
302 intervals. Subsequently, one fetal ovary of each fetus was transported to the laboratory in
303 TRIzol® Reagent for RNA extraction and the other was transported in methacarn solution
304 (60% methanol, 30% chloroform, 10% acetic acid) for histology and immunohistochemistry.

305

306 **2.1.2. Gene expression**

307 For total RNA extraction, the whole fetal ovaries were homogenized (Precellys®, Bertin
308 Technologies) and later subjected to the TRIzol® protocol (Invitrogen®, São Paulo, Brazil) to
309 obtain total RNA in accordance with the manufacturer's instructions. The total RNA
310 concentration was measured by spectrophotometry using a Nanodrop (ND-2000®). The total
311 RNA from samples (1µg) was incubated with DNase (1 U/µg; Invitrogen, Carlsbad, CA,
312 USA) and then reverse transcribed by using a random primer in accordance with protocol
313 provided by High Capacity Kit instructions (Applied Biosystems, Foster City, CA, USA).

314 The RT-qPCR analysis for each gene (LHCGR, LRBP, STAR, HSD3B1, CYP17A1,
315 and CYP19A1) were performed by QuantStudio™ 7 Flex using Power Sybr® Green PCR
316 Master Mix system (Applied Biosystems). The mRNA abundance of target genes was
317 assessed in a total reaction volume of 25 µL, with 1.0 µL of each sample and 24 µL of probe
318 plus primers in accordance with the methods of Machado et al. (2009) for endogenous genes,
319 and Castilho et al. (2015) and Ereno et al. (2015) for the target genes (Table1). The thermal

320 cycling conditions comprised 95°C for 10 min, followed by 40 cycles of denaturing at 95°C
 321 for 10 s, annealing, and extension for 1 min, with different temperatures used for different
 322 genes. These actions were optimized to provide the maximum amplification efficiency for
 323 each gene. The specificity of each PCR product was determined by melting curve analysis.
 324 Each sample was analyzed in duplicate and negative controls were run for each plate.

325 **Table 1**
 326 Primers used in RT-qPCR.
 327

Gene	Forward	Reverse	Final concentration	Temp. annealing (C°)
LHR	5'GCATCCACAAGC TTCCAGATGTTACG A 3'	5'GGGAAATCAGCGTT GTCCCATTGA 3'	300	60
LRBP	5'TGTTGTCAGAAG TCCTGCTGGTGT 3'	5'TAAGTTGAGGCCCA CTCTCCCAT 3'	300	56
CYC A	5'TATCTGCACTGC CAAGACTGAGTG3'	5'CTTCTTGCTGGTCTTGC CATTCC3'	125	60
STAR	5'CCCAGCAGAAGG GTGTCATC 3'	5'TGCGAGAGGACCTG GTTGAT 3'	400	62
CYP19A1	5'CTGAAGCAACAG GAGTCCTAAATGTA CA 3'	5'AATGAGGGGCCCA ATTCCCAGA 3'	400	62
CYP17 A1	5'GTGGAGACCACC ACCTCTGT3'	5'GCTGAAACCCACA TTCTGGT3'	108	67
HSD3B1	5'TCCTTGGCCTC TCTACTCCA3'	5'AGACAGCATATGG GGTCAGC3'	125	62

328
 329
 330 To choose the most stable reference gene for the detailed analyses of fetal ovaries, the
 331 amplification profiles of peptidylprolyl isomerase A (PPIA), glyceraldehyde-3-phosphate
 332 dehydrogenase (GAPDH), and histone H2AFZ (H2AFZ) were compared by using the geNorm
 333 applet for Microsoft Excel (medgen.ugent.be/genorm; (Ramakers et al., 2003)). The most
 334 stable housekeeping gene was PPIA. The $\Delta\Delta C_t$ method with efficiency correction was used to
 335 calculate relative expression values (target genes/PPIA) for each target gene; the mean value
 336 for the day 60 group was used as a calibrator (Pfaffl, 2001).

337

338

2.1.3. miRNA expression

339

The miRNA extraction was performed from 50 µg of total RNA by using a mirVana™

340

miRNA Isolation Kit (Life Technologies®, Carlsbad, USA) in accordance with the

341

manufacturer's instruction and subsequently stored at -80°C. To reverse transcribe target

342

miRNAs (bta-miR-222, Has-miR-191, and RNU-43), we used TaqMan® Reverse

343

Transcription Reagents (Applied Biosystems, Foster City, CA, USA) in accordance with the

344

manufacturer's protocols. The qPCR analyses were performed by QuantStudio™ 7 Flex using

345

TaqMan® Universal PCR Master Mix. The final volume of PCR mix was 20 µL and the

346

cycling conditions were 95°C for 10 min, for enzyme activation, followed for 40 cycles of

347

denaturation (95°C for 15 s) and annealing/extension (60°C for 60 s). All samples were run in

348

duplicate.

349

Table 2

350

Details of miRNA assays used in RT-qPCR.

MiRNA	Mature miRNA Sequence	Code	MiRBase accession number
Has-miR-222	AGCUACAUCUGGCUACUGGGU	002276	MIMAT0000279
Has-miR-191	CAACGGAAUCCCAAAGCAGCUG	002299	MIMAT0000440
RNU43	GAACTTATTGACGGGCGGACAGAACTGT GTGCTGATTGTCACGTTCTGATT	001095	

351

352

To quantify the relative abundance of bta-miR-222, we used the geometric mean of the

353

expression of RNU43 and has-miR-191 as a reference (Table 2). The $\Delta\Delta C_t$ method with

354

efficiency correction was used to calculate the relative expression value (bta-miR-

355

222/RNU43_has-miR-191 geometric mean) with the mean value on day 60 used as the

356

calibrator (Pfaffl, 2001).

357

2.1.4 Immunohistochemistry

358

359 The tissues from all groups were fixed in methacarn for 6h and stored in 70% ethanol.

360 Tissue dehydration was performed by using a series of graded ethanol solutions and the

361 dehydrated tissues were embedded in Paraplast® (Oxford Labware, St. Louis, MO, USA).

362 The blocks were sectioned into 4 µm thick slices and the sections were placed on poly-L-

363 lysine-coated slides, which were deparaffinized and washed. One ovary at each estimated

364 fetal age was subjected to immunohistochemical staining to localize LHR (ab96603, Abcam,

365 Cambridge, UK).

366 The antigens were retrieved at high temperature (100 °C) for 30 min in 10 mM citrate

367 buffer (pH 6.0). Endogenous peroxidase activity was quenched through incubation with 3%

368 H₂O₂ diluted in methanol for 15 min and nonspecific protein binding was blocked by the

369 incubation of the slides in bovine serum albumin (BSA), diluted to 3% in PBS, plus 0.1% NP-

370 40. The primary antibody anti-hCG receptor (ab96603, Abcam, 1/100) was diluted in 1% BSA

371 in PBS plus 0.1% NP-40 and the slides were incubated overnight in this solution at 4 °C. For

372 the immunoperoxidase assay, the slides were rinsed in PBS, incubated with secondary

373 antibody biotinylated Goat Anti-Rabbit IgG H&L (ab97049, Abcam), followed by a

374 VECTASTIN ABC Kit (Vector Laboratories Ltd), and visualized with by using

375 diaminobenzidine. The protocol used was standardized by Mendes et al. (2015). The sections

376 were counterstained with Harris hematoxylin. LHR immunostaining was performed in the

377 corpus luteum of adult bovine ovary (positive control) to confirm the quality of the primary

378 antibody. The negative control was performed in the absence of the primary antibody.

379 2.2. Statistical analysis

380 Data were transformed to logarithms if not normally distributed. ANOVA was used to

381 test for effects of gestational days on the relative abundance of miRNA and target genes. The

382 differences between means were determined by the Tukey test. The analyses were computed


383 by using JMP software (SAS Institute Cary, NC). The data are presented as the mean \pm SEM;
384 and differences were considered significant for $P \leq 0.05$.

385

386 3. Results

387 The expression of the target genes and bta-miR-222 was observed in bovine fetal
388 ovary during gestation. When the effect of gestational day was investigated, the abundance of
389 LHCGR mRNA was lower on day 150 of gestation than on day 60 and 90 ($P=0.04$; Fig. 1A);
390 in contrast, the mRNA abundance of LRBP was higher on day 150 than on day 60 and 90
391 ($P=0.03$; Fig. 1B). Similar to LRBP, the expression of bta-miR-222 was also higher on day
392 150 than days 60 and 90 ($P=0.02$; Fig.1C).


393



394 Fig.1. Relative mRNA abundance of LHCGR (A), LRBP (B), and bta-miR222 (C) in the days 60, 90, 120 and
395 150 of gestation. The data are presented as the mean (\pm S.E.M.). Bars with different letters are significantly
396 different ($P \leq 0.05$).

397


398 The immunolocalization of LHR was demonstrated in the fetal ovary. The LHR
399 protein was found in oogonia, primordial, primary, and secondary follicles (Fig. 2A).
400 Moreover, both oocyte and granulosa cells showed positive results for LHR immunostaining
401 (Fig.2B). Another important finding was the stronger immunoreactivity of LHR in the
402 ovarian cortex (Fig. 2A) than in the medullar region, which also showed positive
403 immunostaining for stromal cells and blood vessels (Fig. 2B).



415 Fig. 2. Representative photomicrographs showing immunolocalization of LHR protein in day 150 bovine fetal
 416 ovary (A and B). Overview LHR staining in cortex (C) and medulla (M) with immunostaining in the ovarian
 417 surface (curve arrow) (A). The ovarian cortex showed granulosa LHR positive cells in secondary (thick arrow),
 418 primary (thin arrow) and primordial (dashed arrow) follicles as well as stromal positive cells (circle) (B). Corpus
 419 luteus (CL) was used as positive control and the adult ovary (C and D) stroma are not stained (ST). Strong
 420 immunoreactivity in cytoplasm of small luteal cells (asterisk) and weak immunoreactivity in large luteal cells
 421 (hashtag) are evident (D). Bars: A and B: 100 μm ; C – D: 50 μm .

422

423 With regarding to the mRNA expression of steroidogenic enzymes, only the
 424 abundance of STAR mRNA was differentially expressed during the development of the fetal
 425 ovary, with a higher expression observed on day 150 than day 60 ($P=0.01$; Fig. 3).



426

427 Fig. 3. Relative mRNA abundance of STAR, HSD3B1, CYP17A1, and CYP19A1 between 60 and 150 days of
 428 gestation. The data were presented as the mean (\pm S.E.M.). Bars with different letters (a and b) are significantly
 429 different ($P \leq 0.05$).

430

431 4. Discussion

432 This is the first study to describe the time-dependent expression patterns of LHR, LRBP,
 433 bta-miR-222, and some steroidogenic enzymes in bovine fetal ovary, which reinforce their
 434 steroidogenic capacity. LH plays a key role in the control of the physiological processes in the
 435 ovary, such as the development of antral follicles and ovulation, and acts via the LH receptor
 436 (Xu et al., 1995; Bao et al., 1997; Fortune, 2001; Garverick et al., 2002; Nogueira et al.,
 437 2007). LHCGR mRNA has been detected in the preantral follicles of rats, rabbits, and pigs
 438 (Eppig, 2001), however, the location of LHR in fetal bovine ovaries was not previously
 439 demonstrated, only in adult ovaries (Braw-Tal and Roth, 2005).

440 It has been proposed that steroids play a regulatory role on preantral folliculogenesis.

441 The appearance of the preantral stages in the ovary has a species-specific temporal pattern. In

442 cattle, all pre-antral stages are manifested in the fetal ovary during pregnancy (Erickson,
443 1966). The data regarding the specific moment of appearance of each preantral category are
444 conflicting. Although Rüsse (1983) reported the appearance of primordial, primary, and
445 secondary follicles at approximately 90, 140, and 210 days of gestation, respectively, Tanaka
446 et al. (2001) observed the same stages of development at approximately 74, 91, and 150 days
447 of gestation. This process involves qualitative and quantitative changes, mainly in the
448 metabolism, follicular structure (Gosden et al., 1997) and steroidogenic production (Yang and
449 Fortune, 2008). Therefore, our results reinforced that the steroidogenic capacity of the fetal
450 ovary maybe related to preantral follicle assembly to guarantee further stages of follicle
451 development.

452 The transcriptional regulation of LHR can be influenced by several factors, particularly
453 in granulosa cells, which are FSH-dependent (Nogueira et al., 2007). The data regarding the
454 time at which the ovarian follicles acquire LHR in the granulosa cells are conflicting. Some
455 authors have demonstrated that the dominant follicle acquires LHR before follicle deviation
456 (Ginther et al., 2001), but other reports show that LHR expression occurs after this step (Xu et
457 al., 1995; Bao et al., 1997; Fortune, 2001). In the present study, we demonstrated that the
458 LHR was present in oogonia, primordial, primary, and secondary follicles and that the
459 expression was not exclusive from granulosa and theca cells, as described in bovine antral
460 follicles (Xu et al., 1995; Bao et al., 1997; Fortune et al., 2001; Garverick et al., 2002;
461 Nogueira et al., 2007). Therefore, we considered that LHR expression may be differentially
462 regulated in the preantral follicle and modified when these follicles become gonadotropin
463 dependent during the later stages of their differentiation.

464 Previous data showed the presence of gonadotropins receptors in the cumulus-oocyte
465 complex (Amsterdam et al., 1976; Bodensteiner et al., 1996; Baltar et al., 2000). In support of
466 these results, Baltar et al. (2000) described the positive and conclusive binding of LH or hCG

467 to LH receptors in the bovine cumulus-oocyte complex. The same findings were described by
468 Teerds and Dorrington (1995), who observed that the cumulus cells of mice possessed LH
469 receptors, although the quantities were smaller than those found in granulosa cells. Our data
470 on the expression of the LH receptor in fetal ovaries agree with Teerds and Dorrington (1995),
471 and Bao et al. (1997), who showed that the receptors were in cumulus cells, granular cells,
472 and preantral follicles but disagree with Eppig (1991) who reported the absence of these
473 receptors in these cells types, and Braw-Tal and Roth (2005) which have detected LHR only
474 in inner Teca cells.

475 The negative correlation between LRBP expression and LHCGR mRNA regulation, at
476 the follicular deviation stage in cattle, was also reported by Ereno et al. (2015). The authors
477 suggested that the lower abundance of LRBP mRNA in dominant follicles was consistent with
478 the involvement of the LHCGR/LRBP system during follicle selection, to ensure the
479 expression of LHCGR mRNA and the acquisition of ovulatory capacity. Similarly, we
480 observed that the decreased abundance of LHCGR was accompanied by an increase in the
481 abundance of LRBP, which suggested that LHCGR in the fetal ovary may be regulated by this
482 protein; therefore, the higher abundance of LRBP on day 150 may contribute to the lower
483 expression of LHCGR in the same period.

484 Post-transcriptional regulation by miRNA in the ovary has been reported in several
485 species (Menon et al., 2013; Troppmann et al., 2014; Menon et al., 2015; Gilchrist et al.,
486 2016). The miRNA expression and their specific roles in bovine ovary were previously
487 reported (Zielak-Steciwko and Evans, 2016) including those of miR-222, which was described
488 by Hossain et al. (2009) as a possible regulator of LHCGR expression .In addition, Salilew-
489 Wondim et al. (2014) demonstrated that the expression of miR-222 in the theca and granulosa
490 cells of bovine antral follicles was lower than that in granulosa cells from bovine dominant
491 follicles. Recently, Santos et al. (2018) demonstrated the expression of bta-miR-222 in adult

492 and fetal bovine tissues (ovary, testicle, spleen, liver, kidney, heart, and brain). In the same
493 study, the authors showed that the abundance of LHCGR mRNA and the expression of bta-
494 miR-222 followed opposite patterns in superstimulated granulosa cells from Nelore cattle.
495 Here, the lower levels of LHCGR on day 150 of gestation could be supported by the
496 upregulation of bta-miR-222; the higher expression may be required to regulate preantral
497 follicle formation, especially during the secondary follicle formation at this time. Based on the
498 findings discussed above, we propose the possibility of a summative effect between bta-miR-
499 222 and LRBP, which promotes LHCGR downregulation in the developing bovine fetal
500 ovary.

501 The production of steroids in the fetal ovary is supported by CYP19A1 (Garverick et al.,
502 2010), CYP11A1, HSD3B1, and CYP17A1 (Quirke et al., 2001) in ruminant fetal ovaries.
503 Nevertheless, in the present study, the mRNA abundance of HSD3B1, CYP17A1, and
504 CYP19A1 was not affected by gestational age, but we could not exclude the post-
505 transcriptional pathways as an explanation of steroid production by the fetal ovary, as
506 described by Yang and Fortune (2008).

507 Although the mRNA encoding steroidogenic enzymes was not regulated, the abundance
508 of STAR was higher on day 150 of gestation than day 60, which coincided with an increase in
509 the number of secondary follicles. In cows, STAR mRNA was previously detected in oocytes,
510 and theca and granulosa cells from early antral follicles (Braw-Tal and Roth, 2005). The
511 formation of the thecal compartment and intense granulosa cell proliferation occurs during the
512 transition from the primary to the early antral stage (Braw-Tal and Yossefi, 1997) at
513 approximately days 150–210 of gestation. Therefore, the consecutive increases in mRNA
514 abundance of STAR could be related to the differentiation and proliferation of granulosa and
515 theca cells.

516 Although fetal ovarian development occurs independently of gonadotrophins, the
517 findings regarding the differential expression of LHR/LRBP suggest that this system could be
518 one more factor that must be regulated to allow the establishment of germ cells and fetal
519 ovarian development. In addition, it could enable better strategies, using hormonal protocols,
520 to take advantage of the reproductive potential of cattle.

521

522 **5. Conclusion**

523 These results suggested the involvement of LHCGR/LRBP regulation with mechanisms
524 related to the development of preantral follicles, especially during the establishment of
525 secondary follicles. Furthermore, the present data reinforced that the reduced expression of
526 LHR mRNA in bovine fetal ovaries on day 150 was related to the higher expression of LRBP
527 and bta-miR-222.

528

529 **6. Conflicts of interest**

530 The authors declare no conflicts of interest and financial, personal, or other relationships
531 with other people or organizations.

532

533 **Aknowledgements**

534 This work was supported by São Paulo Research Foundation (FAPESP) grant
535 [#2013/11480-3, #2015/04505-5] and by CAPES for scholarship to M.P. Chaves.

536 **References**

537 Amsterdam, A., Josephs, R., Lieberman, M.E., Lindner, H.R., 1976. Organization of
538 intramembrane particles in freeze-cleaved gap junctions of rat graafian rollicles:

539 optical-diffraction analysis. *J Cell Sci* 21, 93-105.

540 Baltar, A.E., Oliveira, M.A., Catanho, M.T., 2000. Bovine cumulus/oocyte complex:
541 quantification of LH/hCG receptors. *Mol Reprod Dev* 55, 433-437.

542 Bao, B., Garverick, H.A., Smith, G.W., Smith, M.F., Salfen, B.E., Youngquist, R.S.,
543 1997. Changes in messenger ribonucleic acid encoding luteinizing hormone receptor,
544 cytochrome P450-side chain cleavage, and aromatase are associated with
545 recruitment and selection of bovine ovarian follicles. *Biol Reprod* 56, 1158-1168.

546 Bodensteiner, K.J., Wiltbank, M.C., Bergfelt, D.R., Ginther, O.J., 1996. Alterations in
547 follicular estradiol and gonadotropin receptors during development of bovine antral
548 follicles. *Theriogenology* 45, 499-512.

549 Braw-Tal, R., Roth, Z., 2005. Gene expression for LH receptor, 17 alpha-hydroxylase
550 and StAR in the theca interna of preantral and early antral follicles in the bovine
551 ovary. *Reproduction* 129, 453-461.

552 Braw-Tal, R., Yossefi, S., 1997. Studies in vivo and in vitro on the initiation of follicle
553 growth in the bovine ovary. *J Reprod Fertil* 109, 165-171.

554 Castilho, A.C., da Silva, R.B., Price, C.A., Machado, M.F., Amorim, R.L., Buratini, J.,
555 2014. Expression of fibroblast growth factor 10 and cognate receptors in the
556 developing bovine ovary. *Theriogenology* 81, 1268-1274.

557 Castilho, A.C., Price, C.A., Dalanezi, F., Ereno, R.L., Machado, M.F., Barros, C.M.,
558 Gasperin, B.G., Gonçalves, P.B., Buratini, J., 2015. Evidence that fibroblast growth
559 factor 10 plays a role in follicle selection in cattle. *Reprod Fertil Dev*.

560 Conley, A.J., Bird, I.M., 1997. The role of cytochrome P450 17 alpha-hydroxylase
561 and 3 beta-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal
562 steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals.
563 *Biol Reprod* 56, 789-799.

564 Eppig, J.J., 1991. Maintenance of meiotic arrest and the induction of oocyte
565 maturation in mouse oocyte-granulosa cell complexes developed in vitro from
566 preantral follicles. *Biol Reprod* 45, 824-830.

567 Eppig, J.J., 2001. Oocyte control of ovarian follicular development and function in
568 mammals. *Reproduction* 122, 829-838.

569 Ereno, R.L., Loureiro, B., Castilho, A.C., Machado, M.F., Pegorer, M.F., Satrapa,
570 R.A., Nogueira, M.F., Buratini, J., Barros, C.M., 2015. Expression of mRNA Encoding
571 the LH Receptor (LHR) and LHR Binding Protein in Granulosa Cells from Nelore (*Bos*
572 *indicus*) Heifers Around Follicle Deviation. *Reprod Domest Anim* 50, 952-957.

573 Erickson, B.H., 1966. Development and senescence of the postnatal bovine ovary. *J*
574 *Anim Sci* 25, 800-805.

575 Fortune, J.E., 2001. Selection and maintenance of the dominant follicle: an
576 introduction. *Biol Reprod* 65, 637.

577 Fortune, J.E., Eppig, J.J., 1979. Effects of gonadotropins on steroid secretion by
578 infantile and juvenile mouse ovaries in vitro. *Endocrinology* 105, 760-768.

579 Fortune, J.E., Rivera, G.M., Evans, A.C., Turzillo, A.M., 2001. Differentiation of
580 dominant versus subordinate follicles in cattle. *Biol Reprod* 65, 648-654.

581 Garverick, H.A., Baxter, G., Gong, J., Armstrong, D.G., Campbell, B.K., Gutierrez,

582 C.G., Webb, R., 2002. Regulation of expression of ovarian mRNA encoding
583 steroidogenic enzymes and gonadotrophin receptors by FSH and GH in
584 hypogonadotrophic cattle. *Reproduction* 123, 651-661.

585 Garverick, H.A., Juengel, J.L., Smith, P., Heath, D.A., Burkhart, M.N., Perry, G.A.,
586 Smith, M.F., McNatty, K.P., 2010. Development of the ovary and ontogeny of mRNA
587 and protein for P450 aromatase (arom) and estrogen receptors (ER) alpha and beta
588 during early fetal life in cattle. *Anim Reprod Sci* 117, 24-33.

589 Gilchrist, G.C., Tscherner, A., Nalpathamkalam, T., Merico, D., LaMarre, J., 2016.
590 MicroRNA Expression during Bovine Oocyte Maturation and Fertilization. *Int J Mol*
591 *Sci* 17, 396.

592 Ginther, O.J., Beg, M.A., Bergfelt, D.R., Donadeu, F.X., Kot, K., 2001. Follicle
593 selection in monovular species. *Biol Reprod* 65, 638-647.

594 Gosden, R., Krapez, J., Briggs, D., 1997. Growth and development of the mammalian
595 oocyte. *Bioessays* 19, 875-882.

596 Gutiérrez, C.G., Campbell, B.K., Webb, R., 1997. Development of a long-term bovine
597 granulosa cell culture system: induction and maintenance of estradiol production,
598 response to follicle-stimulating hormone, and morphological characteristics. *Biol*
599 *Reprod* 56, 608-616.

600 Gutierrez, C.G., Ralph, J.H., Telfer, E.E., Wilmut, I., Webb, R., 2000. Growth and
601 antrum formation of bovine preantral follicles in long-term culture in vitro. *Biol Reprod*
602 62, 1322-1328.

603 Hossain, M.M., Ghanem, N., Hoelker, M., Rings, F., Phatsara, C., Tholen, E.,
604 Schellander, K., Tesfaye, D., 2009. Identification and characterization of miRNAs
605 expressed in the bovine ovary. *BMC Genomics* 10, 443.

606 Machado, M.F., Portela, V.M., Price, C.A., Costa, I.B., Ripamonte, P., Amorim, R.L.,
607 Buratini, J., Jr., 2009. Regulation and action of fibroblast growth factor 17 in bovine
608 follicles. *J Endocrinol* 202, 347-353.

609 McNatty, K.P., Heath, D.A., Lundy, T., Fidler, A.E., Quirke, L., O'Connell, A., Smith,
610 P., Groome, N., Tisdall, D.J., 1999. Control of early ovarian follicular development. *J*
611 *Reprod Fertil Suppl* 54, 3-16.

612 Mendes, L.O., Scarano, W.R., Rochel-Maia, S.S., Fioruci-Fontaneli, B.A., Chuffa,
613 L.G., Anselmo-Franci, J.A., Martinez, F.E., 2015. Androgen therapy reverses injuries
614 caused by ethanol consumption in the prostate: testosterone as a possible target to
615 ethanol-related disorders. *Life Sci* 120, 22-30.

616 Menon, B., Gulappa, T., Menon, K.M., 2015. miR-122 Regulates LH Receptor
617 Expression by Activating Sterol Response Element Binding Protein in Rat Ovaries.
618 *Endocrinology* 156, 3370-3380.

619 Menon, B., Sinden, J., Franzo-Romain, M., Botta, R.B., Menon, K.M., 2013.
620 Regulation of LH receptor mRNA binding protein by miR-122 in rat ovaries.
621 *Endocrinology* 154, 4826-4834.

622 Nair, A.K., Kash, J.C., Peegel, H., Menon, K.M., 2002. Post-transcriptional regulation
623 of luteinizing hormone receptor mRNA in the ovary by a novel mRNA-binding protein.
624 *J Biol Chem* 277, 21468-21473.

625 Nogueira, M.F.G., Buratini, J., Jr., Price, C.A., Castilho, A.C.S., Pinto, M.G.L., Barros,
626 C.M., 2007. Expression of LH receptor mRNA splice variants in bovine granulosa
627 cells: Changes with follicle size and regulation by FSH in vitro. *Molecular*
628 *Reproduction and Development* 74, 680-686.

629 Pfaffl, M.W., 2001. A new mathematical model for relative quantification in real-time
630 RT-PCR. *Nucleic Acids Res* 29, e45.

631 Quirke, L.D., Juengel, J.L., Tisdall, D.J., Lun, S., Heath, D.A., McNatty, K.P., 2001.
632 Ontogeny of steroidogenesis in the fetal sheep gonad. *Biol Reprod* 65, 216-228.

633 Ramakers, C., Ruijter, J.M., Deprez, R.H., Moorman, A.F., 2003. Assumption-free
634 analysis of quantitative real-time polymerase chain reaction (PCR) data. *Neurosci*
635 *Lett* 339, 62-66.

636 Rüsse, I., 1983. Oogenesis in cattle and sheep. *Bibl Anat* 24, 77-92.

637 Salilew-Wondim, D., Ahmad, I., Gebremedhn, S., Sahadevan, S., Hossain, M.D.,
638 Rings, F., Hoelker, M., Tholen, E., Neuhoff, C., Looft, C., Schellander, K., Tesfaye,
639 D., 2014. The expression pattern of microRNAs in granulosa cells of subordinate and
640 dominant follicles during the early luteal phase of the bovine estrous cycle. *PLoS One*
641 9, e106795.

642 Santos, P.H., Satrapa, R.A., Fontes, P.K., Franchi, F.F., Razza, E.M., Mani, F.,
643 Nogueira, M.F.G., Barros, C.M., Castilho, A.C.S., 2018. Effect of superstimulation on
644 the expression of microRNAs and genes involved in steroidogenesis and ovulation in
645 Nelore cows. *Theriogenology* 110, 192-200.

646 Shemesh, M., Allenberg, M., Milaguir, F., Ayalon, N., Hansel, W., 1978. Hormone
647 secretion by cultured bovine pre- and postimplantation gonads. *Biol Reprod* 19, 761-
648 767.

649 Tanaka, Y., Nakada, K., Moriyoshi, M., Sawamukai, Y., 2001. Appearance and
650 number of follicles and change in the concentration of serum FSH in female bovine
651 fetuses. *Reproduction* 121, 777-782.

652 Teerds, K.J., Dorrington, J.H., 1995. Immunolocalization of transforming growth
653 factor alpha and luteinizing hormone receptor in healthy and atretic follicles of the
654 adult rat ovary. *Biol Reprod* 52, 500-508.

655 Troppmann, B., Kossack, N., Nordhoff, V., Schüring, A.N., Gromoll, J., 2014.
656 MicroRNA miR-513a-3p acts as a co-regulator of luteinizing hormone/chorionic
657 gonadotropin receptor gene expression in human granulosa cells. *Mol Cell*
658 *Endocrinol* 390, 65-72.

659 Wandji, S.A., Srsen, V., Voss, A.K., Eppig, J.J., Fortune, J.E., 1996. Initiation in vitro
660 of growth of bovine primordial follicles. *Biol Reprod* 55, 942-948.

661 Webb, R., Nicholas, B., Gong, J.G., Campbell, B.K., Gutierrez, C.G., Garverick, H.A.,
662 Armstrong, D.G., 2003. Mechanisms regulating follicular development and selection
663 of the dominant follicle. *Reprod Suppl* 61, 71-90.

664 Xu, Z., Garverick, H.A., Smith, G.W., Smith, M.F., Hamilton, S.A., Youngquist, R.S.,
665 1995. Expression of messenger ribonucleic acid encoding cytochrome P450 side-
666 chain cleavage, cytochrome p450 17 alpha-hydroxylase, and cytochrome P450
667 aromatase in bovine follicles during the first follicular wave. *Endocrinology* 136, 981-

668 989.

669 Yang, M.Y., Fortune, J.E., 2008. The capacity of primordial follicles in fetal bovine
670 ovaries to initiate growth in vitro develops during mid-gestation and is associated with
671 meiotic arrest of oocytes. *Biol Reprod* 78, 1153-1161.

672 Zielak-Steciwko, A.E., Evans, A.C., 2016. Genomic portrait of ovarian follicle growth
673 regulation in cattle. *Reprod Biol* 16, 197-202.

674



ANIMAL REPRODUCTION SCIENCE

An International Journal

AUTHOR
INFORMATION
PACK



ISSN: 0378-4320

TABLE OF CONTENTS

- **Description** p.1
- **Audience** p.1
- **Impact Factor** p.1
- **Abstracting and Indexing** p.2
- **Editorial Board** p.2 • **Guide for Authors** p.3

DESCRIPTION

Animal Reproduction Science publishes original research and timely reviews on topics relating to **reproduction** and **fertility** in **animals**. This includes both fundamental research and applied studies, including management practices that increase our understanding of the **biology** and **manipulation** of reproduction. The focus is on animals that are useful to humans including food- and fibre-producing; companion/recreational; captive; and endangered species including zoo animals, but excluding laboratory animals unless the study reveals new information that impacts our basic understanding of the biology or manipulation of reproduction applicable to the animals listed above.

The journal's scope includes the study of reproductive physiology and endocrinology, reproductive cycles, natural and artificial control of reproduction, preservation and use of gametes and embryos, pregnancy and parturition, infertility and sterility, diagnostic and therapeutic techniques.

Animal Reproduction Science has decided not to publish papers that exclusively examine the *in vitro* development of oocytes and embryos; however, it will consider papers that include *in vitro* studies where the source of the oocytes and/or development of the embryos beyond the blastocyst stage is part of the experimental design.

Authors with any concerns are encouraged to contact the journal to enquire about the suitability of the content of their paper for [submission](#). *Animal Reproduction Science* has no page charges and only publishes papers after rigorous peer review.

AUDIENCE

Research Workers in Animal and Human Reproduction, Animal Health Workers.

IMPACT FACTOR

ABSTRACTING AND INDEXING

Biological Abstracts
Current Awareness in Biological Sciences
PubMed
MEDLINE®
Animal Breeding Abstracts
Bibliography of Reproduction
Current Contents/Agriculture, Biology & Environmental Sciences
Scopus
Elsevier BIOBASE

EDITORIAL BOARD

Co-Editors-in-Chief

G.N. Hinch, University of New England, Armidale, NSW, Australia
J.E. Kinder, Ohio State University, Wooster, OH, USA

Editorial Advisory Board

B.M. Alexander, Laramie, WY USA
L.L. Anderson, Ames, IA USA
C. Aurich, Vienna, Austria
F.W. Bazer, College Station, TX USA
H. Cardenas, Columbus, OH USA
J.F. Cavalieri, Townsville, QLD, Australia
D. Cavestany, Montevideo, Uruguay
P. Comizzoli, Washington, DC USA
R.A. Cushman, Clay Center, NE USA
R.A. Dailey, Morgantown, WV USA
S.P. de Graaf, Sydney, NSW, Australia
J.A. Delgadillo, Torreón, Coahuila, Mexico
M.G. Diskin, Athenry, County Galway, Ireland
M-A. Driancourt, Chateaufeuf sur Sarthe, France
A.D. Ealy, Gainesville, FL USA
W.L. Flowers, Raleigh, NC USA
J. Ford, Maryville, MO, USA
D.L. Garner, Reno, NV USA
C.L. Gasser, Cedar City, UT USA
W.V Holt, London, UK
K. Imakawa, Tokyo, Japan
A.L. Johnson, University Park, PA USA
R.J. Mapletoft, Saskatoon, SK, Canada
J.F. Mee, Fermoy, County Cork, Ireland
J.C.F. Moraes, Bage, Brazil
T. Nagai, Taipei, Taiwan, China
N. Parvizi, Neustadt, Germany
J.R. Pursley, East Lansing, MI USA
J.P. Ravindra, Bangalore, India
R.R. Santos, Lelystad, Netherlands
D.C. Sharp, Gainesville, FL USA
Y-L. Shiue, Kaohsiung, Taiwan
J.F. Smith, Auckland, New Zealand
D.L. Thompson, Baton Rouge, LA USA
A. Turner, Burwood, VIC Australia
S. Uzbekova, Nouzilly, France
M. Yeste, Girona, Spain

GUIDE FOR AUTHORS

INTRODUCTION

Types of Paper

1. Original Research Papers (Regular Papers)
2. Review Articles

Original Research Papers should report the results of research that comprises one or a series of experiments. The paper should contribute to increasing our understanding of the biology and/or manipulation of reproduction in animals. The material should not have been previously published elsewhere, except in a preliminary form.

Review Articles Review manuscripts should fit within the scope for the journal and be of current interest in the realm of animal reproduction in those species on which the journal focuses. Submission of Review Manuscripts to Animal Reproduction Science is encouraged. The manuscripts may be submitted without invitation or be invited reviews and should be submitted using the same process as that for Original Research manuscripts.

Contact details for submission

For queries concerning the submission process or journal procedures please visit the [Elsevier Support Center](#). Authors can check the status of their manuscript within the review procedure using Elsevier Editorial System.

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

Manuscript:

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)

Supplemental files (where applicable)

Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including theInternet)
- A competing interests statement is provided, even if the authors have no competing interests todeclare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

Revisions

Revisions:

Please ensure when submitting a revision to complete and include the '[Revision Checklist](#)' file.

BEFORE YOU BEGIN

Ethics in publishing

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

Human and animal rights

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association \(Declaration of Helsinki\)](#) for experiments involving humans; [Uniform Requirements for manuscripts submitted to Biomedical journals](#). Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](#) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](#), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.

Unnecessary cruelty in animal experimentation is not acceptable to the Editors of *Animal Reproduction Science*.

Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/ registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see '[Multiple, redundant or concurrent publication](#)' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

Authorship

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Changes to authorship

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the

reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

Elsevier supports responsible sharing

Find out how you can [share your research](#) published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

Open access

This journal offers authors a choice in publishing their research:

Subscription

- Articles are made available to subscribers as well as developing countries and patient groups throughout [universal access programs](#).
- No open access publication fee payable by authors.

Open access

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- An open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee for this journal is **USD 2500**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

Green open access

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [green open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more](#).

This journal has an embargo period of 12 months.

Elsevier Researcher Academy

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

Please submit your article via <https://www.evise.com/profile/api/navigate/ANIREP>.

Referees

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](#). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

PREPARATION

Peer review

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is

responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

Article structure

Manuscripts should have numbered lines with wide margins and double spacing throughout, i.e. also for abstracts, footnotes and references. Every page of the manuscript, including the title page, references, tables, etc., should be numbered. However, in the text no reference should be made to page numbers; if necessary, one may refer to sections. Avoid excessive usage of italics to emphasize part of the text.

Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

The introduction "sets the scene" for your work. Do not over-reference statements; two or three key references should suffice unless each adds something specific. The introduction should not normally be more than 500 words (approximately two manuscript pages).

Material and methods

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results

Results should be clear and concise.

Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required of not more than 250 words. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-

standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images and in accordance with all technical requirements.

Highlights

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view [example Highlights](#) on our information site.

Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors and editors are, by general agreement, obliged to accept the rules governing biological nomenclature, as laid down in the *International Code of Botanical Nomenclature*, the *International Code of Nomenclature of Bacteria*, and the *International Code of Zoological Nomenclature*.

All botica (crops, plants, insects, birds, mammals, etc.) should be identified by their scientific names when the English term is first used, with the exception of common domestic animals.

All biocides and other organic compounds must be identified by their Geneva names when first used in the text. Active ingredients of all formulations should be likewise identified.

Nomenclature and units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. You are urged to consult [IUB: Biochemical Nomenclature and Related Documents](#) for further information.

Math formulae

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork

Electronic artwork General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed [guide on electronic artwork](#) is available.

You are urged to visit this site; some excerpts from the detailed information are given here. *Formats*

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi. TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

Tables

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#) and [Zotero](#), as well as [EndNote](#). Using the word processor plugins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/animal-reproduction-science>

When preparing your manuscript, you will then be able to select this style using the Mendeley plugins for Microsoft Word or LibreOffice.

Reference style

Text: All citations in the text should refer to:

1. *Single author:* the author's name (without initials, unless there is ambiguity) and the year of publication;
2. *Two authors:* both authors' names and the year of publication;
3. *Three or more authors:* first author's name followed by 'et al.' and the year of publication. Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have recently shown'

List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:

Reference to a journal publication:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. *J. Sci. Commun.* 163, 51–59.

Reference to a book:

Strunk Jr., W., White, E.B., 2000. *The Elements of Style*, fourth ed. Longman, New York.

Reference to a chapter in an edited book:

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E-Publishing Inc., New York, pp. 281–304.

Reference to a website:

Cancer Research UK, 1975. Cancer statistics reports for the UK. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13 March 2003).

Reference to a dataset:

[dataset] Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak wilt disease and surrounding forest compositions. Mendeley Data, v1. <https://doi.org/10.17632/xwj98nb39r.1>.

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. . In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. [More information and examples are available](#). Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Data visualization

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions [here](#) to find out about available data visualization options and how to include them with your article.

Supplementary material

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on

depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

Data linking

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Mendeley Data

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

Data statement

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

AFTER ACCEPTANCE

Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is

accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Webshop](#). Corresponding authors who have published their article open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>